Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.38 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4302457 | 0.84 | QPCT (0.36) | QPCTQPCTLCYP1A2METAP2 | |
| SCHEMBL27773542 | 0.75 | HSD17B10 (0.37) | DYRK1AHSD17B10GAASMN1; SMN2KDM4E | |
| SCHEMBL4011684 | 0.72 | CYP3A4 (0.36) | DYRK1AHSD17B10GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL10568312 | 0.72 | QPCT (0.38) | QPCTQPCTLCYP1A2METAP2DHFR | |
| SCHEMBL13920402 | 0.70 | CD274 (0.40) | QPCTQPCTLCYP1A2METAP2PIK3CA | |
| SCHEMBL4011604 | 0.70 | HSD17B10 (0.52) | DYRK1AHSD17B10GAAALDH1A1DHFR | |
| SCHEMBL4016522 | 0.69 | DYRK1A (0.40) | DYRK1APDPK1HSD17B10GAAALDH1A1 | |
| SCHEMBL12044436 | 0.68 | CRHR1 (0.43) | QPCTQPCTLCYP1A2METAP2HSD17B10 | |
| SCHEMBL13920403 | 0.68 | PDE4A (0.39) | QPCTQPCTLCYP1A2METAP2HSD17B10 | |
| SCHEMBL23519011 | 0.68 | QPCT (0.36) | QPCTQPCTLCYP1A2METAP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | QPCT 836/4885QPCTL 2600/4885DYRK1A 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.